# A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

Source: https://onco.cc/trials/nct03459846/  
OnCo record `nct03459846` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Durvalumab and Olaparib in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) is a phase 2 interventional study registered as NCT03459846 by AstraZeneca, with 154 participants enrolled, started 2018-03-16 and due to reach its primary completion in 2020-10-15. Interventions recorded: Durvalumab, Olaparib and Placebo. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: BAYOU
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03459846
- Phase: 2
- Setting: A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
- Sponsor: AstraZeneca
- Enrolled: 154
- Outcomes: Progression-free Survival (PFS): Durva + Olaparib 4.2 months vs Durva + Placebo 3.5 months, HR 0.94

## Sources

- ClinicalTrials.gov NCT03459846: https://clinicaltrials.gov/study/NCT03459846

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Muscle-invasive and advanced bladder cancer](https://onco.cc/cancers/muscle-invasive-bladder-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct03459846.json